232 related articles for article (PubMed ID: 32944756)
1. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort).
Scailteux LM; Campillo-Gimenez B; Kerbrat S; Despas F; Mathieu R; Vincendeau S; Balusson F; Happe A; Nowak E; Oger E
Am J Epidemiol; 2021 Feb; 190(3):413-422. PubMed ID: 32944756
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
3. Sequential Use of Androgen Receptor Axis-targeted Agents in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Retrospective Analysis With 3-Year Follow-up.
Kobayashi T; Terada N; Kimura T; Matsubara N; Murakami K; Mori K; Fujimoto Y; Akamatsu S; Inoue T; Ogawa O
Clin Genitourin Cancer; 2020 Feb; 18(1):e46-e54. PubMed ID: 31759831
[TBL] [Abstract][Full Text] [Related]
4. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment.
Badrising S; van der Noort V; van Oort IM; van den Berg HP; Los M; Hamberg P; Coenen JL; van den Eertwegh AJ; de Jong IJ; Kerver ED; van Tinteren H; Bergman AM
Cancer; 2014 Apr; 120(7):968-75. PubMed ID: 24382803
[TBL] [Abstract][Full Text] [Related]
5. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series.
Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
Clin Genitourin Cancer; 2015 Jun; 13(3):193-8. PubMed ID: 25466676
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
7. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
Terada N; Maughan BL; Akamatsu S; Kobayashi T; Yamasaki T; Inoue T; Kamba T; Ogawa O; Antonarakis ES
Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
[TBL] [Abstract][Full Text] [Related]
8. Comparative Assessment of Efficacies Between 2 Alternative Therapeutic Sequences With Novel Androgen Receptor-Axis-Targeted Agents in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Clin Genitourin Cancer; 2017 Aug; 15(4):e591-e597. PubMed ID: 28063845
[TBL] [Abstract][Full Text] [Related]
9. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
10. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis.
Mori K; Miura N; Mostafaei H; Quhal F; Sari Motlagh R; Pradere B; Kimura S; Kimura T; Egawa S; Briganti A; Karakiewicz PI; Shariat SF
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):539-548. PubMed ID: 32152435
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Pereira-Salgado A; Kwan EM; Tran B; Gibbs P; De Bono J; IJzerman M
Eur Urol Focus; 2021 Jul; 7(4):752-763. PubMed ID: 32273196
[TBL] [Abstract][Full Text] [Related]
12. Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review.
Zhang W; Wu TY; Chen Q; Shi XL; Xiao GA; Zhao L; Xu CL; Zhou T; Sun YH
Asian J Androl; 2017; 19(2):196-202. PubMed ID: 27212123
[TBL] [Abstract][Full Text] [Related]
13. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
Wang X; Yang H; Hu X; Wang W; Yu X; Wang S; Zhang X; Liu L
J Oncol Pharm Pract; 2021 Apr; 27(3):614-622. PubMed ID: 32529950
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
15. [Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
Richter I; Dvořák J; Hejzlarová V; Chalupa J; Sochor M; Stankuš I; Barsová L; Holikova M; Forster J; Bartoš J
Klin Onkol; 2016; 29(2):127-32. PubMed ID: 27081803
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Automated Bone Scan Index in Men With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate.
Miyoshi Y; Uemura K; Kawahara T; Yoneyama S; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Yao M; Uemura H
Clin Genitourin Cancer; 2017 Aug; 15(4):472-478. PubMed ID: 28110835
[TBL] [Abstract][Full Text] [Related]
17. Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide.
Pilon D; Behl AS; Ellis LA; Emond B; Lefebvre P; Dawson NA
J Manag Care Spec Pharm; 2017 Feb; 23(2):225-235. PubMed ID: 28125362
[TBL] [Abstract][Full Text] [Related]
18. Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide.
Scailteux LM; Vincendeau S; Gravis G; Mathieu R; Balusson F; Kerbrat S; Oger E
Clin Genitourin Cancer; 2023 Oct; 21(5):e362-e369. PubMed ID: 37188606
[TBL] [Abstract][Full Text] [Related]
19. Abiraterone acetate, enzalutamide and their sequence for castration-resistant prostate cancer : Adherence, survival and hospitalization analysis of a medical claims database.
Al-Ali BM; Eredics K; Madersbacher S; Schauer I
Wien Klin Wochenschr; 2018 Nov; 130(21-22):659-664. PubMed ID: 30324300
[TBL] [Abstract][Full Text] [Related]
20. A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment.
Kawahara T; Kato M; Tabata K; Kojima I; Yamada H; Kamihira O; Tsumura H; Iwamura M; Uemura H; Miyoshi Y
BMC Cancer; 2020 Sep; 20(1):919. PubMed ID: 32977754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
